Table 1. Distribution of clinicopathological characteristics in the study cohort and correlation with cytoplasmic and nuclear RelA expression.

	All cases	RelA cytoplasmic negative	RelA cytoplasmic positive	P-values	RelA nuclear negative	RelA nuclear positive	P-values
All cases	82	40 (48.8%)	42 (51.2%)		45 (54.9%)	37 (45.1%)
Age (years)
⩽65	42 (51.2%)	20 (47.6%)	22 (52.4%)	1.000a	23 (54.8%)	19 (45.2%)	1.000a
>65	40 (48.8%)	20 (50%)	20 (50%)		22 (55%)	18 (45%)
Tumour stage
T1	1 (1.2%)	1 (100%)	0 (0%)	0.062b	1 (100%)	0 (0%)	0.050b
T2	30 (36.6%)	17 (56.7%)	13 (43.3%)		19 (63.3%)	11 (36.7%)
T3	48 (58.5%)	22 (45.8%)	26 (54.2%)		25 (52.1%)	23 (47.9%)
T4	3 (3.7%)	0 (0%)	3 (100%)		0 (0%)	3 (100%)
Nodal status
N0	26 (31.7%)	17 (65.4%)	9 (34.6%)	0.057a	18 (69.2%)	8 (30.8%)	0.097a
N1	56 (68.3%)	23 (41.1%)	33 (58.9%)		27 (48.2%)	29 (51.8%)
Lymph vessel invasion
L0	54 (65.9%)	22 (40.7%)	32 (59.3%)	0.062a	28 (51.9%)	26 (48.1%)	0.490a
L1	28 (34.1%)	18 (64.3%)	10 (35.7%)		17 (60.7%)	11 (39.3%)
Blood vessel invasion
V0	71 (86.6%)	34 (47.9%)	37 (52.1%)	0.753a	39 (54.9%)	32 (45.1%)	1.000a
V1	11 (13.4%)	6 (54.5%)	5 (45.5%)		6 (54.5%)	5 (45.5%)
Grade
G1	8 (9.8%)	2 (25%)	6 (75%)	0.939b	4 (50%)	4 (50%)	0.205b
G2	43 (52.4%)	25 (58.1%)	18 (41.9%)		28 (65.1%)	15 (34.9%)
G3	31 (37.8%)	13 (41.9%)	18 (58.1%)		13 (41.9%)	18 (58.1%)
RelA nuclear
Negative	45 (54.9%)	33 (73.3%)	12 (26.7%)	<0.001a	—	—
Positive	37 (45.1%)	7 (18.9%)	30 (81.1%)		—	—

^aFisher's exact test.

^bχ² test for trends.